During his “compulsory ‘me’ time” at his local café in Byron Bay, Australia in September 2017, David received an email about a new international Phase III clinical trial for Waldenstrom’s macroglobulinemia (WM), comparing two targeted therapies –...
If you are interested in sharing your story with us so that we may share it with others on our website, please submit your contact details.